• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Deloitte Releases 12th Annual Life Sciences Industry Accounting Guide

Article

Report provides comprehensive look at financial and accounting issues faced by life sciences industry.

On Mar. 16 Deloitte released its 12th annual Life Sciences Industry Accounting Guide. The report provides a comprehensive look at some of the complex issues that finance and accounting professionals in the life sciences industry face including R&D costs, acquisitions and divestitures, consolidation, contingencies, revenue recognition, income taxes, financial instruments, and financial statement presentation and disclosure.

Some of the main themes from this year’s edition include:

  • COVID-19-Related Accounting and Financial Reporting Considerations for Life Sciences Entities
  • IPOs and SPACs
  • Revenue Recognition
  • Structured Trade Payable Arrangement

For additional information and the full report, click here.

Related Content
AbbVie, EvolveImmune Therapeutics Strike Deal to Develop Biotherapeutics for Resistant Cancer Cells

AbbVie, EvolveImmune Therapeutics Strike Deal to Develop Biotherapeutics for Resistant Cancer Cells

Don Tracy, Associate Editor
October 31st 2024
Article

The deal is expected to leverage EvolveImmune's T-cell engager EVOLVE platform to develop novel antibody-based therapies for solid and hematologic malignancies.

GSK Agrees to Terms to Acquire Novel Treatment for Autoimmune Diseases from Chimagen Biosciences

GSK Agrees to Terms to Acquire Novel Treatment for Autoimmune Diseases from Chimagen Biosciences

Don Tracy, Associate Editor
October 29th 2024
Article

CMG1A46 is currently being developed for B cell-driven autoimmune diseases, primarily systemic lupus erythematosus and lupus nephritis.

AbbVie Agrees to Terms to Acquire Aliada Therapeutics

AbbVie Agrees to Terms to Acquire Aliada Therapeutics

Don Tracy, Associate Editor
October 28th 2024
Article

Acquisition includes Aliada’s lead asset, ALIA-1758, which is being developed for the treatment of Alzheimer disease.

AbbVie, Gedeon Richter Ink Deal to Develop Novel Targets for Neuropsychiatric Conditions

AbbVie, Gedeon Richter Ink Deal to Develop Novel Targets for Neuropsychiatric Conditions

Don Tracy, Associate Editor
October 25th 2024
Article

Under terms of the deal, Richter will receive an upfront cash payment of $25 million, along with potential future development, regulatory, and commercialization milestones.

Report: Radiopharmaceutical Market Expected to Reach $26.51 Billion by 2031

Report: Radiopharmaceutical Market Expected to Reach $26.51 Billion by 2031

Don Tracy, Associate Editor
October 25th 2024
Article

Growth is expected due to increased instances of chronic diseases such as cancer and Alzheimer disease.

Merck Agrees to Terms to Acquire Modifi Biosciences

Merck Agrees to Terms to Acquire Modifi Biosciences

Don Tracy, Associate Editor
October 24th 2024
Article

Under terms of the deal, Merck will provide an upfront payment of $30 million, with potential milestone payments of up to $1.3 billion for the Yale University spinout that develops targeted therapies for cancer.